|Mr. Michael Macaluso||Founder, Chairman and Chief Exec. Officer||305k||N/A||65|
|Dr. David Bar-Or M.D.||Chief Scientific Officer and Director||305k||N/A||68|
|Mr. Philip H. Coelho||Director||89k||N/A||73|
|Mr. Thomas E Chilcott III||Interim Chief Financial Officer & Controller||N/A||N/A||N/A|
Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee; and Optina, which has completed Phase II clinical trials for diabetic macular edema. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.
Ampio Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 7. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 4; Compensation: 9.